Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort

BACKGROUND: Programmed cell death protein‐1‐targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma. AIM: To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real‐world cohort of patients with advanced hepatocell...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheiner, Bernhard, Kirstein, Martha M., Hucke, Florian, Finkelmeier, Fabian, Schulze, Kornelius, von Felden, Johann, Koch, Sandra, Schwabl, Philipp, Hinrichs, Jan B., Waneck, Fredrik, Waidmann, Oliver, Reiberger, Thomas, Müller, Christian, Sieghart, Wolfgang, Trauner, Michael, Weinmann, Arndt, Wege, Henning, Trojan, Jörg, Peck‐Radosavljevic, Markus, Vogel, Arndt, Pinter, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Programmed Cell Death Protein‐1 Targeted Immunotherapy for Hepatocellular Carcinoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593858/
https://www.ncbi.nlm.nih.gov/pubmed/30980420
http://dx.doi.org/10.1111/apt.15245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593858/
https://www.ncbi.nlm.nih.gov/pubmed/30980420
http://dx.doi.org/10.1111/apt.15245

Ejemplares similares